Please check your internet connection and try again.
# IV Hydrocortisone for Acute Asthma
## Overview
Hydrocortisone is a short-acting synthetic glucocorticoid used in the emergency management of acute asthma exacerbations. Systemic corticosteroids accelerate the resolution of airflow obstruction, decrease relapse rates, and reduce the need for hospital admission.
## Primary Indications
Treatment of acute, severe asthma exacerbations unresponsive to initial intensive bronchodilator therapy. Generally reserved for patients unable to tolerate oral corticosteroids.
## Adult Dosing
* **Initial Dose:** 100 mg IV every 6 to 8 hours.
* **Maximum Dose:** No strict physiological maximum for acute management, but clinical practice typically defaults to 400 mg/day in divided doses. Transition to oral prednisone/prednisolone as soon as the patient can tolerate oral medications.
## Pediatric Dosing
* **Initial Dose:** 2 mg/kg to 4 mg/kg IV per dose.
* **Frequency:** Every 6 hours.
* **Maximum Dose:** 100 mg per dose.
* **Note:** Always verify dosing against current institutional/local clinical pathways, as asthma protocols vary significantly by site.
## Dose Adjustments
* **Hepatic/Renal Impairment:** No specific adjustment required for acute, short-term usage.
* **Long-term use:** If therapy extends beyond 5–7 days, consider tapering to avoid HPA-axis suppression.
## Contraindications
* Hypersensitivity to hydrocortisone or any component of the formulation.
* Systemic fungal infections.
* Avoid live or attenuated vaccines during high-dose therapy.
## Adverse Effects
* **Common:** Hyperglycemia (especially in diabetic patients), hypertension, fluid retention, hypokalemia, and insomnia.
* **Serious:** Psychosis, peptic ulcer disease, and increased susceptibility to infection with prolonged use.
## Key Drug Interactions
* **CYP3A4 Inducers (e.g., Phenytoin, Rifampin, Phenobarbital):** May decrease hydrocortisone efficacy.
* **Loop/Thiazide Diuretics:** Increased risk of hypokalemia.
* **NSAIDs:** Increased risk of gastrointestinal ulceration.
* **Antidiabetics:** Corticosteroids may antagonize the therapeutic effects of insulin and oral hypoglycemics.
## Monitoring
* **Clinical:** Respiratory rate, oxygen saturation, and peak expiratory flow (PEF) or FEV1.
* **Laboratory:** Blood glucose (closely monitor in patients with known diabetes) and serum electrolytes (potassium) if therapy is extended.
* **Signs of clinical deterioration:** Escalating oxygen requirements or signs of respiratory fatigue.
## Clinical Pearls
* **Transition to Oral:** Systemic corticosteroids should be transitioned to an oral equivalent (e.g., prednisone or prednisolone) as soon as the patient is stable and can tolerate oral intake.
* **Speed of Action:** IV corticosteroids have a delayed onset; clinical improvement generally occurs after 3–4 hours. They are not substitutes for inhaled beta-agonists.
* **Local Protocols:** Institutional protocols for asthma management differ; consult your local pharmacy department or clinical guidelines (e.g., GINA or EPR-4) for site-specific treatment algorithms.
***
**Educational Disclaimer:** This information is for educational purposes only. Always verify doses, contraindications, and drug interactions against the most current prescribing information, institutional protocols, and primary literature before administration. Seek guidance from a specialized clinical pharmacist or physician for individual patient care.
